Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000395095

Medchemexpress LLC (8R,9S)-Talazoparib ((8R,9S)-BMN-673) | 1207456-00-5 | 98.3% | 380.35 | 100 MG
SDP

Catalog No. 5000395095
Encompass_Preferred

(8R,9S)-Talazoparib is an enantiomer of Talazoparib and acts as a PARP1 inhibitor with an IC50 of 144 nM. This product is for research use only.

  • Acts as a PARP-1 inhibitor with an IC50 of 144 nM.
  • Exhibits an EC50 of 1135 nM for cytotoxicity against BRCA2-deficient human Capan1 cells.
  • Shows an EC50 of 864 nM for inhibition of PARP in human LoVo cells.
  • Demonstrates a GI50 of 1807 nM for potentiation of temozolomide-induced cytotoxicity in human LoVo cells.
  • Displays an EC50 of 864 nM in cellular PARylation assay.
  • Shows an EC50 of 1135 nM for Capan-1 cells (BRCA2 mutant).

Catalog No. 50-003-95095 Supplier Medchemexpress LLC Supplier No. HY16106A100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

(8R,9S)-Talazoparib is an enantiomer of Talazoparib and acts as a PARP1 inhibitor with an IC50 of 144 nM. This product is for research use only.

  • Acts as a PARP-1 inhibitor with an IC50 of 144 nM.
  • Exhibits an EC50 of 1135 nM for cytotoxicity against BRCA2-deficient human Capan1 cells.
  • Shows an EC50 of 864 nM for inhibition of PARP in human LoVo cells.
  • Demonstrates a GI50 of 1807 nM for potentiation of temozolomide-induced cytotoxicity in human LoVo cells.
  • Displays an EC50 of 864 nM in cellular PARylation assay.
  • Shows an EC50 of 1135 nM for Capan-1 cells (BRCA2 mutant).

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.